⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15548548 | 0.80 | — | — | |
| SCHEMBL4316592 | 0.63 | — | — | |
| SCHEMBL3220863 | 0.59 | FSCN1 (0.30) | — | |
| SCHEMBL16279273 | 0.59 | — | — | |
| SCHEMBL380104 | 0.58 | — | — | |
| SCHEMBL7258133 | 0.54 | — | — | |
| SCHEMBL1650923 | 0.53 | — | — | |
| SCHEMBL1654819 | 0.53 | — | — | |
| SCHEMBL1064651 | 0.53 | — | — | |
| SCHEMBL350137 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720337-B2 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxlmic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2004-04-13 | — | — | US | disclosed |
| EP-1401425-A1 | ORGANOMETALLIC ANTI-TUMOUR AGENT | Haemato-Basics GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-6656955-B2 | Side effect reduction; synergistic mixture | N-GENE RESEARCH LABORATORIES, INC. | 2003-12-02 | — | — | US | disclosed |
| WO-2003004014-A1 | ORGANOMETALLIC ANTI-TUMOUR AGENT | HAEMATO-BASICS GMBH (DE) | 2003-01-16 | — | — | WO | disclosed |
| US-6440998-B1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2002-08-27 | — | — | US | disclosed |